Sunday 18 October 2026
Export HURA’s income statement to Excel — free account
TuHURA Biosciences, Inc.
HURA Healthcare Biotechnology
In the quarter to June 2026, EPS grew 33.3% and free cash flow fell 70.5%, each against the same quarter a year earlier.
1.76
0.07
−3.83%
Follow HURA
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(327.03%) | (171.92%) | (190.42%) | (163.84%) | |
| (196.36%) | (127.05%) | (139.51%) | (92.31%) | ||
ROIC |
(130.13%) | (114.79%) | (119.54%) | (74.20%) | |
Return on Tangible Assets |
581.82% | 3,013.26% | (2,491.74%) | 427.57% | |
Average Days of Receivables |
— | 0.00 | — | — | |
Free Cash Flow per Share |
(0.41) | (0.58) | (0.44) | (0.47) | |
Free Cash Flow |
(20.81) | (27.71) | (26.28) | (29.90) | |
Capital Expenditures |
3.86 | (0.08) | 1.03 | (0.21) | |
| Other line items | |||||
Cash ROIC |
(106.85%) | (112.84%) | (89.11%) | (105.78%) | |
Accounts Receivable Turnover |
— | 0.00 | — | — | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(54.36) | (50.85) | (49.45) | (27.83) | |
Operating CF/Net income |
0.84 | 0.92 | 0.88 | 0.97 | |
Depreciation/Fixed assets |
0.80 | 1.84 | 1.72 | 2.01 | |
Capex/Depreciation |
16.25 | (0.14) | 1.83 | (0.24) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.49) | (0.58) | (0.45) | (0.46) | |
Capex per Share |
0.08 | 0.00 | 0.02 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates